Skip to main content

Table 3 Comparison of clinical features, disease activity and organ damage accrual at diagnosis and last visit

From: Comparison of clinical features, disease activity, treatment and outcomes between late-onset and early-onset patients with systemic lupus erythematosus. A sex- and year at diagnosis-matched controlled study

Variables

At diagnosis

At last visit

Late-onset SLE (N = 62)

Early-onset SLE (N = 124)

p value

Late-onset SLE (N = 62)

Early-onset SLE (N = 124)

p1 value

p2 value

Malar rashes

9 (14.5)

46 (37.1)

0.001

11 (17.7)

56 (45.2)

0.001

0.152

Discoid rashes

25 (40.3)

46 (37.1)

0.669

26 (41.9)

53 (42.7)

0.947

0.425

Oral ulcers

13 (21.0)

43 (34.7)

0.055

14 (22.6)

52 (41.9)

0.024

0.130

Photosensitivity

11 (17.7)

21 (16.9)

0.891

13 (21.0)

26 (21.0)

0.889

0.956

Arthritis

26 (41.9)

77 (62.1)

0.009

32 (51.6)

82 (66.1)

0.081

0.315

Serositis

23 (37.0)

18 (14.5)

0.001

24 (38.7)

28 (22.6)

0.011

0.403

Pleuritis, n (%)

17 (27.4)

14 (11.3)

0.005

17 (27.4)

17 (13.7)

0.010

0.980

Pericarditis, n (%)

10 (16.1)

11 (8.9)

0.140

12 (19.4)

18 (14.5)

0.422

0.779

Renal disorder, n (%)

29 (46.8)

60 (48.4)

0.836

33 (53.2)

92 (74.2)

0.008

0.002

Neurologic disorder

7 (11.3)

8 (6.5)

0.253

9 (14.5)

17 (13.7)

0.795

0.331

Seizures, n (%)

5 (8.1)

3 (2.4)

0.074

7 (11.3)

6 (4.8)

0.088

0.684

Psychosis, n (%)

2 (3.2)

5 (4.0)

0.785

2 (3.2)

11 (8.9)

0.226

0.219

Hematologic disorder, n (%)

52 (83.9)

101 (81.5)

0.684

54 (87.1)

106 (85.5)

0.562

0.990

Hemolytic anemia, n (%)

31 (50.0)

42 (33.9)

0.034

35 (56.5)

60 (48.4)

0.308

0.369

Leukopenia, n (%)

20 (32.3)

62 (50.0)

0.022

21 (33.9)

66 (53.2)

0.025

0.418

Lymphopenia, n (%)

31 (50.0)

82 (66.1)

0.034

31 (50.0)

85 (68.5)

0.041

0.198

Thrombocytopenia, n (%)

15 (24.2)

23 (18.5)

0.368

16 (25.8)

34 (27.4)

0.938

0.193

ANA, n/N (%)

62/62 (100.0)

123/123 (100.0)

1

62/62 (100.0)

123/123 (100.0)

1

1

Anti-dsDNA, n/N (%)

37/48 (77.1)

76/98 (77.6)

0.949

38/54 (70.4)

96/117 (82.1)

0.149

0.049

No. of ACR criteria, mean (95% CI)

4.82 (4.53–5.11)

5.04 (4.81–5.27)

0.268

5.26 (4.99–5.23)

5.94 (5.69–6.18)

0.005

0.008

mSLEDAI-2K scores, mean (95% CI)a

7.41 (5.98-9.00)

7.50 (6.48–8.59)

0.927

0.41 (0.13–0.85)

0.57 (0.29–0.93)

0.006

0.253

SDI scores, mean (95% CI)a

0.37 (0.20–0.58)

0.02 (0.01–0.04)

< 0.001

1.37 (0.95–1.86)

0.47 (0.31–0.66)

< 0.001

0.341

  1. a = transformed data, p1 value = p value adjusted by disease duration, p2 value = p value adjusted by disease duration and value of baseline variables
  2. ACR = American College of Rheumatology, ANA = anti-nuclear antibody, anti-dsDNA = anti-double stranded DNA antibody, mSLEDAI-2K = modified systemic lupus erythematosus disease activity index-2000, n/N = number of positive tests/number of tested, SDI = systemic lupus international collaborating clinics/American College of Rheumatology damage index, SLE = systemic lupus erythematosus